These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34534628)

  • 1. BORIS/CTCFL expression activates the TGFβ signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma.
    Makani VKK; Mendonza JJ; Edathara PM; Yerramsetty S; Pal Bhadra M
    Free Radic Biol Med; 2021 Nov; 176():62-72. PubMed ID: 34534628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of BORIS/CTCFL leads to ROS-dependent cellular senescence and drug sensitivity in MYCN-amplified neuroblastoma.
    Rao GK; Makani VKK; Mendonza JJ; Edathara PM; Patel N; Ramakrishna M; Cilamkoti P; Chiring Phukon J; Jose J; Bhadra U; Bhadra MP
    FEBS J; 2022 May; 289(10):2915-2934. PubMed ID: 34854238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
    Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
    Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
    Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
    Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
    Debruyne DN; Dries R; Sengupta S; Seruggia D; Gao Y; Sharma B; Huang H; Moreau L; McLane M; Day DS; Marco E; Chen T; Gray NS; Wong KK; Orkin SH; Yuan GC; Young RA; George RE
    Nature; 2019 Aug; 572(7771):676-680. PubMed ID: 31391581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
    Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
    Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
    Nguyen P; Cui H; Bisht KS; Sun L; Patel K; Lee RS; Kugoh H; Oshimura M; Feinberg AP; Gius D
    Cancer Res; 2008 Jul; 68(14):5546-51. PubMed ID: 18632606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CTCFL/BORIS for the immunotherapy of cancer.
    Loukinov D
    Cancer Immunol Immunother; 2018 Dec; 67(12):1955-1965. PubMed ID: 30390146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
    Alberti L; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Widespread expression of BORIS/CTCFL in normal and cancer cells.
    Jones TA; Ogunkolade BW; Szary J; Aarum J; Mumin MA; Patel S; Pieri CA; Sheer D
    PLoS One; 2011; 6(7):e22399. PubMed ID: 21811597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the epigenetic factor BORIS (CTCFL) in the human genome.
    de Necochea-Campion R; Ghochikyan A; Josephs SF; Zacharias S; Woods E; Karimi-Busheri F; Alexandrescu DT; Chen CS; Agadjanyan MG; Carrier E
    J Transl Med; 2011 Dec; 9():213. PubMed ID: 22168535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the CTCFL Gene during Mouse Embryogenesis Causes Growth Retardation, Postnatal Lethality, and Dysregulation of the Transforming Growth Factor β Pathway.
    Sati L; Zeiss C; Yekkala K; Demir R; McGrath J
    Mol Cell Biol; 2015 Oct; 35(19):3436-45. PubMed ID: 26169830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes.
    Hore TA; Deakin JE; Marshall Graves JA
    PLoS Genet; 2008 Aug; 4(8):e1000169. PubMed ID: 18769711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Diverging Routes of BORIS and CTCF: An Interactomic and Phylogenomic Analysis.
    Jabbari K; Heger P; Sharma R; Wiehe T
    Life (Basel); 2018 Jan; 8(1):. PubMed ID: 29385718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.
    Pugacheva EM; Teplyakov E; Wu Q; Li J; Chen C; Meng C; Liu J; Robinson S; Loukinov D; Boukaba A; Hutchins AP; Lobanenkov V; Strunnikov A
    Epigenetics Chromatin; 2016; 9(1):35. PubMed ID: 27588042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
    Link PA; Zhang W; Odunsi K; Karpf AR
    Cancer Immun; 2013; 13():6. PubMed ID: 23390377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
    Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
    PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression.
    Nguyen P; Bar-Sela G; Sun L; Bisht KS; Cui H; Kohn E; Feinberg AP; Gius D
    Mol Cell Biol; 2008 Nov; 28(21):6720-9. PubMed ID: 18765639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTCF and BORIS in genome regulation and cancer.
    Marshall AD; Bailey CG; Rasko JE
    Curr Opin Genet Dev; 2014 Feb; 24():8-15. PubMed ID: 24657531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.